Epigene Labs focuses on advanced genomic technologies to enhance the understanding and treatment of various diseases. Their primary offerings include innovative solutions for epigenetic analysis, which allows for the examination of gene expression regulation and cellular behavior. By leveraging cutting-edge techniques, Epigene Labs aims to provide insights into the molecular mechanisms underlying diseases, facilitating the development of targeted therapies and personalized medicine approaches.

The company emphasizes the importance of high-throughput sequencing and bioinformatics in their research and product development. These technologies enable the comprehensive analysis of epigenetic modifications across different cell types and conditions, leading to a deeper understanding of how these changes influence health and disease. Through their commitment to scientific excellence and technological innovation, Epigene Labs is positioned to contribute significantly to the field of genomics and improve patient outcomes through tailored therapeutic strategies.

France

Epigene Labs is creating the intelligence-augmenting solution for precision oncology research and drug development. Designed by cancer scientists for cancer scientists, the company's mCUBE platform accelerates data-driven drug discovery, biomarker identification, and patient selection -- to bring better treatments to patients faster. Based in Paris and Boston, Epigene Labs was initially incubated at the Harvard Innovation Labs and launched in France with the support of prominent European investors. Epigene Labs has partnerships with world-class cancer research institutes and biopharmaceutical companies.

Epigene Labs

Company Details